scispace - formally typeset
S

Sarah L. Morgan

Researcher at University of Alabama at Birmingham

Publications -  163
Citations -  4711

Sarah L. Morgan is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Rheumatoid arthritis & Osteoporosis. The author has an hindex of 32, co-authored 152 publications receiving 4145 citations. Previous affiliations of Sarah L. Morgan include University of South Alabama & University of Alabama.

Papers
More filters
Journal ArticleDOI

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

TL;DR: In those patients at high risk for the development of ONJ, including cancer patients receiving high‐dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage.
Journal ArticleDOI

Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial

TL;DR: A larger and longer study to evaluate different doses of folic acid, assuming that toxicity could be reduced without changing the efficacy of methotrexate, and the influence of the folic Acid dose on metotrexate toxicity and efficacy remains controversial.
Journal ArticleDOI

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis.

TL;DR: It is concluded that a daily supplement of 1 mg of FA during low-dose MTX therapy (median dose 7.5 mg/week [16.4 mumoles]) is usefull in lessening toxicity without altering efficacy during the first 6 months of treatment.
Journal ArticleDOI

Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ

Aliya Khan, +37 more
TL;DR: A case-based review of ONJ and application of the International Task Force recommendations for the diagnosis and management of oncology and osteoporosis patients is provided.